SCNX Stock Overview
Operates as health services IT company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Scienture Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.81 |
| 52 Week High | US$13.42 |
| 52 Week Low | US$6.29 |
| Beta | 0 |
| 11 Month Change | -4.76% |
| 3 Month Change | 1.56% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCNX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -6.8% | 7.9% | 1.6% |
| 1Y | n/a | 16.0% | 32.3% |
Return vs Industry: Insufficient data to determine how SCNX performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how SCNX performed against the US Market.
Price Volatility
| SCNX volatility | |
|---|---|
| SCNX Average Weekly Movement | 10.2% |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SCNX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Suren Ajjarapu | scienture.com |
Scienture Holdings, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics, and independent pharmacies. Scienture Holdings, Inc. is headquartered in Tampa, Florida.
Scienture Holdings, Inc. Fundamentals Summary
| SCNX fundamental statistics | |
|---|---|
| Market cap | US$62.22m |
| Earnings (TTM) | -US$10.25m |
| Revenue (TTM) | n/a |
-191.1x
P/S Ratio-6.6x
P/E RatioIs SCNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCNX income statement (TTM) | |
|---|---|
| Revenue | -US$351.61k |
| Cost of Revenue | -US$991.80k |
| Gross Profit | US$640.19k |
| Other Expenses | US$10.89m |
| Earnings | -US$10.25m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | -182.07% |
| Net Profit Margin | 2,916.21% |
| Debt/Equity Ratio | 3.0% |
How did SCNX perform over the long term?
See historical performance and comparison